# Evaluation of Cardioverter Capacity of Amiodarone Pre-electrical Cardioversion in Persistent Atrial Fibrillation

Study · id `cardio:ct-nct06645249` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06645249](<https://clinicaltrials.gov/study/NCT06645249>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06645249

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 122 participants.

## Technical summary

Registry record NCT06645249. Randomized; no masking; primary purpose treatment. Start 2024-12-10 (anticipated); primary completion 2026-09 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 122 participants (planned count; ClinicalTrials.gov record NCT06645249, source copy `cardio:ctgov-nct06645249-2024-12-02`, retrieved 2026-10-26)
- Planned start: 2024-12-10 (anticipated) (ClinicalTrials.gov record NCT06645249, source copy `cardio:ctgov-nct06645249-2024-12-02`, retrieved 2026-10-26)
- Primary completion: 2026-09 (anticipated) (ClinicalTrials.gov record NCT06645249, source copy `cardio:ctgov-nct06645249-2024-12-02`, retrieved 2026-10-26)
- Completion: 2026-10 (anticipated) (ClinicalTrials.gov record NCT06645249, source copy `cardio:ctgov-nct06645249-2024-12-02`, retrieved 2026-10-26)
- Countries: Spain (ClinicalTrials.gov record NCT06645249, source copy `cardio:ctgov-nct06645249-2024-12-02`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06645249-2024-12-02`, retrieved 2026-10-26)

## The registry's words

- Brief title: Evaluation of Cardioverter Capacity of Amiodarone Pre-electrical Cardioversion in Persistent Atrial Fibrillation
- Acronym: PERIVERSION
- Condition: Atrial Fibrillation (AF)
- Intervention (Drug): Amiodarone (Antiarrhythmic drug)
- Lead sponsor: Institut Investigacio Sanitaria Pere Virgili
- Lead sponsor class: OTHER
- Collaborator: Spanish Society of Cardiology
- Collaborator class: OTHER
- Collaborator: Sociedad Espanola de Cardiologia
- Collaborator class: UNKNOWN

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Amiodarone (`cardio:amiodarone`)
- Registry lists this organization as a collaborator: Spanish Society of Cardiology (`cardio:org-spanish-society-of-cardiology`)

## Provenance

Content hash: 06262df584b4e31d94c90a037ae0078c4a91a5912a972a51da2bec70b89abd33
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
